ARIX.L

Arix Bioscience Plc
Arix Bioscience Plc - Director/PDMR Shareholding
2nd May 2023, 14:52
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1654Y
Arix Bioscience Plc
02 May 2023
 

Arix Bioscience plc
("Company")

PDMR notifications & Director Shareholdings

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Arix Bioscience Plc has been notified of the following transactions relating to the below named PDMRs and their respective interests in the ordinary share capital of the Company ('Shares'):

Peregrine Moncreiffe, Non-Executive Director and Chairman of the Board purchased 75,000 Ordinary shares of 0.001 pence each in the Company ("Shares") on 27 April 2023 at a price of 102.5 pence per share and purchased a further 85,000 Shares in the Company on 28 April 2023 at a price of 104.8 pence per share.  

Debra Barker, Non-Executive Director and Senior Independent Director purchased 24,000 Shares in the Company on 27 April 2023 at a price of 103 pence per share.

Robert Lyne, Chief Executive Officer purchased 24,330 Shares in the Company on 27 April 2023 at a price of 102.75 pence per share.

In a separate transaction, Robert Lyne exercised vested options over 203,764 shares ("Option Shares") on 27 April 2023 pursuant to a nil cost share award granted on 30 June 2020. 96,107 of the Shares were sold on 27 April 2023 at a sale price of 101.5 pence per share to satisfy the resultant income tax and National Insurance liability.

The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further detail on the respective transactions.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Peregrine Moncreiffe

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director and Chair of the Board

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

  c)

Price(s) and volume(s)


Price(s)£

Volume(s)


27 April           2023

28 April          2023


1.025

1.048                                        

75,000     

85,000

                              

 

 


d)

 

Aggregated information


- Aggregated volume

160,000

- Price

£165,962.50

e)

 

Date of the transaction

 

27 April 2023                                                                                                        28 April 2023

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne  

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share Purchase 

 c)

Price(s) and volume(s)


Price(s)£

Volume(s)




£1.0275

 

 

24,330


d)

 

Aggregated information


- Aggregated volume

N/A (Single Transaction)

- Price

£24,999.08

e)

 

Date of the transaction

 

27 April 2023

f)

 

Place of the transaction

 

London Stock Exchange

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne  

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Vesting of awards under the Company's Executive Incentive Plan ("EIP") 2020 and sale of shares to cover associated tax liabilities

 c)

Price(s) and volume(s)


Price(s)£

Volume(s)




1.)      Acquisition £nil per share

 

2.)       Disposal £1.015

 

 

203,764

 

96,107


d)

 

Aggregated information


- Aggregated volume

N/A (Single Transaction)

- Price

 £97,548.61

e)

 

Date of the transaction

 

27 April 2023

f)

 

Place of the transaction

 

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Debra Barker

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Share purchase

  c)

Price(s) and volume(s)


Price(s) £

£1.03.00          

Volume(s)

24,000


d)

 

Aggregated information


- Aggregated volume

N/A (single transaction)

- Price

£24,720.00

e)

 

Date of the transaction

 

27 April 2023                                                                                                       

f)

 

Place of the transaction

 

London Stock Exchange

 

Ends.

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
 +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZLLFBXELEBBF ]]>
TwitterFacebookLinkedIn